BC Platforms, a world leader in genomic data management and analytics, today announces that it has signed a co-operation agreement with Abomics to promote a novel pharmacogenetics technology to Healthcare and Life Science customers globally. Both companies work in the front line of genomics data and will provide a premium, integrated solution to healthcare providers globally.
Incoming data will be processed by BC Platforms' high performing genomic data management platform and the pharmacogenetic status will be interpreted by Abomics' machine learning PGx interpretation service. This service will enable clinical practitioners to have more confidence in providing treatment recommendations while reducing the chance of adverse effects experienced by their patients.
Read the entire article here.